Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines

Gene editing

Home » Emerging technologies » Gene editing

Inscripta

Inscripta Launches the World’s First Benchtop Platform for Digital Genome Engineering

The Onyx™ platform enables scientists to create libraries of millions of precisely engineered single cells in one experiment through a fully automated workflow October 01, 2019 08:00 AM Eastern Daylight Time BOULDER...

Genome Editing Biotech EdiGene Raises $11 M in Series Pre-B2 Financing and Forms Research Collaboration to Develop Allogeneic T-cell Therapeutics for Cancer

Inscripta Appoints Jim Lalonde to Lead Microbial Digital Genome Engineering Business and Portfolio Strategy

September 05, 2019 08:00 AM Eastern Daylight Time BOULDER, Colo.–(BUSINESS WIRE)–Inscripta, Inc., developer of the first benchtop platform for scalable Digital Genome Engineering, today named Jim Lalonde, Ph...

Inscripta Expands Management Team with Appointment of Three Senior Bioinformatics and Computational Biology Experts

The Alliance for Regenerative Medicine Releases Statement of Principles on Genome Editing

CRISPR Clinical Trials: A 2019 Update

Richard Fox

Gene editing reborn: A conversation with Inscripta’s Richard Fox

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results

Building with Bio

Research roundup: Artificial cells respond to their environment, protein nanowires, and a new CRISPR algorithm

Sangamo Announces Nature Biotechnology Publication of New Strategies for Optimizing the Specificity of Gene Editing Nucleases

In research news this week: Smart cell therapies, new base editing technology, synthetic cells, and more

Twist Bioscience Launches Long Oligos to Fuel Drug Development, DNA Data Storage and Gene Editing Research

SynBioBeta Webinar “CRISPR Enabled Trackable Engineering (CREATE): Bringing Genome Engineering to the Bench”

apoptosis

Synthetic biology news from the lab bench #4

MilliporeSigma

MilliporeSigma and Broad Institute Announce CRISPR License Framework to Encourage Innovation